Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Share-based Compensation (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Share-based Compensation readings, the most recent being $822000.0 for Q1 2026.

  • Quarterly Share-based Compensation fell 5.19% to $822000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Mar 2026, up 54.26% year-over-year, with the annual reading at $3.8 million for FY2025, 84.46% up from the prior year.
  • Share-based Compensation hit $822000.0 in Q1 2026 for DiaMedica Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.2 million in Q4 2025 and bottomed at $308000.0 in Q1 2022.
  • Average Share-based Compensation over 5 years is $584588.2, with a median of $456000.0 recorded in 2023.
  • The largest annual shift saw Share-based Compensation plummeted 39.73% in 2022 before it skyrocketed 102.38% in 2025.
  • DiaMedica Therapeutics' Share-based Compensation stood at $411000.0 in 2022, then increased by 10.95% to $456000.0 in 2023, then rose by 29.17% to $589000.0 in 2024, then skyrocketed by 102.38% to $1.2 million in 2025, then plummeted by 31.04% to $822000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Share-based Compensation are $822000.0 (Q1 2026), $1.2 million (Q4 2025), and $1.0 million (Q3 2025).